MOONLAKE IMMUNOTHERAPEUTICS Shareholders' Equity
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Shareholders' Equity of $428.19 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $428.19M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $254.02M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $304.48M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $288.91M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $428.19M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $254.02M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $304.48M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $288.91M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $353.73M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $407.52M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $446.82M 10-K · filed 2026-02-25 | $446.83M 10-K · filed 2025-02-26 |
| 2024-09-30 | $488.20M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $520.66M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $542.55M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $495.68M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $424.93M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $489.80M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $42.00M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $48.90M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $55.29M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $63.51M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $24.40M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$11.65M 10-K · filed 2023-03-20 | -$7.06M 10-K · filed 2022-02-17 |
| 2021-09-30 | -$4.84M 10-Q/A · filed 2021-12-14 | |
| 2021-06-30 | $5.00M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$2.59M 10-Q · filed 2022-05-16 | $5.00M 10-Q · filed 2021-05-21 |
| 2020-12-31 | -$2.52M 10-K · filed 2022-02-17 | $5.00M 10-K · filed 2021-03-31 |
| 2020-09-30 | $20.00K 10-Q · filed 2020-12-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |